← Back to guidelines
Otolaryngology (ENT)18 papers

Neoplasm of parotid gland

Last edited: 4/15/2026

Overview

Recurrent pleomorphic adenoma (RPA) of the parotid gland represents a challenging clinical scenario characterized by tumor recurrence post-initial surgical excision. Management requires careful consideration of resection completeness, patient risk factors, and potential adjuvant therapies.

Diagnosis

  • Imaging: MRI recommended preoperatively to assess tumor extension and detect subclinical lesions 1.
  • Surgical Assessment: Consider neuromonitoring during surgery to preserve function 1.
  • Management

  • Primary Treatment: Complete resection under neuromonitoring is recommended 1.
  • Adjuvant Therapy: Radiotherapy considered for multi-recurrent cases, incomplete resections, or non-operable scenarios at high risk of recurrence 1.
  • Special Populations

  • Younger Patients: Higher risk of progression and malignant transformation necessitates careful monitoring and aggressive management 1.
  • Key Recommendations

  • Perform complete resection with neuromonitoring for recurrent pleomorphic adenomas of the parotid gland to minimize functional sequelae (Evidence: Strong 1).
  • Utilize MRI preoperatively to evaluate tumor extent and identify subclinical lesions (Evidence: Moderate 1).
  • Consider radiotherapy in cases of multi-recurrent pleomorphic adenomas, following incomplete resection, or in non-operable scenarios with high recurrence risk (Evidence: Moderate 1).
  • References

    1 Malard O, Thariat J, Cartier C, Chevalier D, Courtade-Saidi M, Uro-Coste E et al.. Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part II: Management of recurrent pleomorphic adenoma of the parotid gland. European annals of otorhinolaryngology, head and neck diseases 2021. link

    Original source

    1. [1]
      Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part II: Management of recurrent pleomorphic adenoma of the parotid gland.Malard O, Thariat J, Cartier C, Chevalier D, Courtade-Saidi M, Uro-Coste E et al. European annals of otorhinolaryngology, head and neck diseases (2021)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG